Connect with us

Media & Technology

Telco Cuba Inc (OTCMKTS: QBAN) Powerful Run Brewing as Co Looks to Acquire Internet and Cable Television Service Provider & Subsidiary Advanced Satellite Systems Signs 10-year Agreement with City of Hawthorne

Published

on

Telco Cuba Inc (OTCMKTS: QBAN) is making a powerful move to the upside in recent days looking to break out into pennyland. The stock is getting noticed by some big players in small caps and at current market valuation this one has plenty of room to grow. Currently under heavy accumulation QBAN as emerged in recent days as an investor favorite and traded over 1.5 billion shares on Tuesday alone on several million in dollar volume for the day. QBAN is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – a break over $0.0045 and its blue skies ahead for QBAN.   

It’s easy to get excited QBAN at current levels; “Pink Current” the Company recently stated its intention of up listing its shares to fully reporting OTCQB and beyond. Telco Cuba, expects to be convertible and promissory note debt free and cash flow positive within the next 24 months. The Company has been building up its BOD recently appointing Mr. Patrick T. Wall and Mrs. Camille Whiddon an Account executive from Uniti Fiber (NASDAQ: UNIT), to its board of directors. QBAN currently operates via its 3 subsidiaries including Advanced Satellite Systems which recently signed a 10 year agreement with City of Hawthorne and is awaiting a $1.4 million payout from the FCC for repack expenses. Management states Advanced is expecting more revenue opportunities from Government grants as well as expanding its services to include 4K & HD television services. QBAN management has been working hard behind the scenes and is currently on the lookout to acquire an internet & cable television service provider as well as embark on a global sales expansion. 

Telco Cuba Inc (OTCMKTS: QBAN) is a holding company dedicated to amassing a portfolio of high value companies in the telecom space. Telco Cuba, Inc. currently has subsidiaries offering collocation, hosting, software development, and technology consulting services in the South Florida area. Telco Cuba, Inc. is in the market for technology oriented acquisitions that provide residual income in the technology services industry. 

QBAN operates via its subsidiaries including Advanced Satellite Systems, Inc.; an Internet, Cable Television, and Telephone Service provider, located in Ormond Beach, FL. The company services the areas of Port Orange, Daytona Shores, Daytona Beach, Holly Hills, Ormond Beach in Volusia County and the City of Flagler Beach, in Flagler County.  Incorporated in 1985, the company has been providing services to residential, commercial, and academic clients for over 35 years. The company is going through a restructuring affecting its marketing and sales departments.  Forthcoming, the company will announce its new address, website and implement new internal procedures aimed towards streamlining and maximizing leads to sales cycles.  The company will be focusing its efforts onto offering commercial services. 

Amgentech, Inc. is a premier provider of colocation, hosting, software development, website development and VoIP services in the South Florida region.  The company was established in 2001 to provide infrastructure and information security services. Amgentech, Inc. has been instrumental in the launch of a plethora of products and services, including the site and product offerings of www.brandonlang.comwww.sportsadvisors.comwww.sportsline.comwww.starmedia.com, as well as offshore providers of sports related services.  Our 99.999% uptime SLA’s, bulk mail services and know-how have enabled the company to keep customers long term.  

To Find out the inside Scoop on QBAN Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

QBAN

South Florida Interactive provides compelling, eye-catching website designs coupled with the latest software development techniques to ensure a responsive, highly available customer point of contact. 

QBAN subsidiary Advanced Satellite Systems, Inc. recently signed a 10 year agreement with the City of Hawthorne, FL for the use of its current cable television and Internet infrastructure, including the city owned earth base station.  Telco Cuba is consulting with its partners on the eventual roll out of a FTTH/FTTP – Fiber to the Home, Fiber to the Premise offering, with the goal of providing compelling and currently unavailable services in the city of Hawthorne, and the surrounding unincorporated areas. On the heels of the City of Hawthorne contract, and several other ongoing negotiations, the company is embarking on another potentially lucrative opportunity, which has the potential to progressively increase the company’s subscriber base by over 13,000 subscribers. 

Earlier this year, the FCC issued an updated incumbent earth station list, in which the FCC confirms the current status of the Company’s land earth stations with regards to the FCC accepted list for lump sum recipients.  The list is referred by the CBAND-RPC (C Band Relocation Payment Clearinghouse) in determining payments to be made to operators. On July 23rd, 2021, the FCC issued overlay licenses to Auction 107 winning bidders.  According to the CBAND-RPC, the issuance of the overlay license was the necessary milestone that would trigger winning bidders to fund the payments to companies whose lump sum claims have been accepted by the FCC.  QBAN is awaiting the CBAND-RPC’s advisement about the next steps to claim the funds allocated to Advanced Satellite Systems. The Company is awaiting a $1.4 million lump sum payment from the FCC. 

Up-listing to OTCQB and beyond is a clear goal for the company, every corporate action taken to date is in preparation for the eventuality. The Company’s proposed name change announcement by FINRA is pending the audit of several financial statements due prior to filing form 15 with the SEC. MK&A CPAs has been engaged to audit those statements.  Once complete and filed, QGAN will resubmit its request to FINRA to announce its name change. The Company intends to continue auditing its financials, and become an SEC Filer by filing an S1 registration. The company will be convertible and promissory debt free by the end of the year as a result of its capitalization initiatives. The company filed a “FORM 1 A” circular with the SEC on August 18th 2021. The purpose of the circular is to request permission from the SEC to sell registered securities to accredited investors. The proceeds from the Form 1A circular are intended primarily to grow Advanced Satellite Systems’ subscriber base by acquiring a cable system in our geographic footprint area.  

For more on QBAN Subscribe Right Now!

QBAN is making a powerful move to the upside in recent days looking to break out into pennyland. The stock is getting noticed by some big players in small caps and at current market valuation this one has plenty of room to grow. Currently under heavy accumulation QBAN as emerged in recent days as an investor favorite and traded over 1.5 billion shares on Tuesday alone on several million in dollar volume for the day. QBAN is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – a break over $0.0045 and its blue skies ahead for QBAN. It’s easy to get excited QBAN at current levels; “Pink Current” the Company recently stated its intention of up listing its shares to fully reporting OTCQB and beyond. Telco Cuba, expects to be convertible and promissory note debt free and cash flow positive within the next 24 months. The Company has been building up its BOD recently appointing Mr. Patrick T. Wall and Mrs. Camille Whiddon an Account executive from Uniti Fiber (NASDAQ: UNIT), to its board of directors. QBAN currently operates via its 3 subsidiaries including Advanced Satellite Systems which recently signed a 10 year agreement with City of Hawthorne and is awaiting a $1.4 million payout from the FCC for repack expenses. Management states Advanced is expecting more revenue opportunities from Government grants as well as expanding its services to include 4K & HD television services. QBAN management has been working hard behind the scenes and is currently on the lookout to acquire an internet & cable television service provider as well as embark on a global sales expansion. We will be updating on QBAN so make sure you Subscribe to Microcapdaily so you know what’s going on with QBAN.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in QBAN either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.